The Institute of Cancer Research has launched the world’s first ‘Darwinian’ cancer drug programme, aiming to deliver step change in cancer treatment. The programme is specially designed to tackle cancer’s lethal ability to evolve resistance to treatment and is to be launched in a £75 million state-of-the-art global centre of expertise in anti-evolution therapies in
Cardiff University plans to launch the new Medicines Discovery Institute, increasing the development of new drugs for mental health such as anxiety and central nervous system conditions. The institute, which is part funded by the Welsh Government, the Higher Education Funding Council for Wales and the European Regional Development Fund, will develop novel medications to
Cancer Research UK’s Commercial Partnerships Team and The Institute of Cancer Research, announced a multi-project collaboration and licensing deal with Merck, a leading science and technology company, to discover and develop new anticancer drugs. “It is an exciting example of how successful academic networks and the scale of industry can combine to advance scientific and
A £10 million Future Vaccine Manufacturing Hub led by Imperial College London has been officially launched. The Hub, which involves various research partners, will be led by Professor Robin Shattock from Imperial’s Department of Medicine and involves scientists across Departments of Chemical Engineering and Life Sciences. The researchers at the Hub aim to improve the
Ground-breaking method of delivering lifesaving drugs using microbubbles is moving closer to being used in patients, due to a new research project between Medicines Discovery Catapult and the University of Leeds at Medicines Discovery Catapult’s laboratories in Alderley Park. Due to toxic side effects, many life-saving and life-improving drugs cannot be used to treat patients.
Innovate UK, UK’s innovation agency originally known as the Technology Strategy Board, has awarded nearly £1million in funding to a consortium developing a platform for production of a new family of antibiotics. The partnership, which is formed between industrial biotechnology company Ingenza and the National Physical Laboratory and the University of Plymouth, is creating a
Vernalis and Servier’s partnership has been successfully running for 10 years, the collaboration takes advantage of Vernalis’ proprietary fragment and structure-based drug discovery platform, and of Servier’s expertise in medicinal chemistry, cancer biology and pharmacology to bring innovation in oncology one step further. The collaboration focuses on complicated molecular targets, some of which, such as